[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100344002":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":37,"centralContacts":41,"locations":47,"responsibleParty":64,"collaborators":24,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":22,"acronym":24,"eligibilityCriteria":71,"healthyVolunteers":68,"sex":72,"minAge":73,"maxAge":24,"enrollmentInfo":74,"targetDuration":24,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":24,"overallStatus":49,"whyStopped":24,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"University of Rochester","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Baseline PET","EXPERIMENTAL","R-CHOP",[13,14,15,16,17],"Drug: Rituximab Prednisone","Drug: Cyclophosphamide","Drug: Doxorubicin","Drug: Vincristine","Drug: Prednisone",[19,25,28,31,34],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Rituximab Prednisone","A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma",[9],null,{"type":20,"name":26,"description":22,"armGroupLabels":27,"otherNames":24},"Cyclophosphamide",[9],{"type":20,"name":29,"description":22,"armGroupLabels":30,"otherNames":24},"Doxorubicin",[9],{"type":20,"name":32,"description":22,"armGroupLabels":33,"otherNames":24},"Vincristine",[9],{"type":20,"name":35,"description":22,"armGroupLabels":36,"otherNames":24},"Prednisone",[9],[38],{"name":39,"affiliation":5,"role":40},"Carla Casulo","PRINCIPAL_INVESTIGATOR",[42],{"name":43,"role":44,"phone":45,"phoneExt":24,"email":46},"Robin Boerman","CONTACT","585-273-1507","Robin_Boerman@URMC.Rochester.edu",[48],{"facility":5,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"RECRUITING","Rochester","New York","14642","United States","US",{"type":56,"coordinates":57},"Point",[58,59],-77.61556,43.15478,{"lat":59,"lon":58},[62],{"name":63,"role":44,"phone":24,"phoneExt":24,"email":24},"Andrew Bui",{"type":40,"investigatorFullName":39,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"Associate Professor of Hematology\u002FOncology","100344002","phase-2-a-study-of-pet-adapted-therapy-and-non-invasive-monitoring-for-previously-untreated-limited-stage-diffuse-large-b-cell-lymphoma-100344002",false,"NCT03758989","A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma","Inclusion Criteria:\n\n* Previously untreated limited stage non bulky DLBCL; defined as limited stage by routine staging criteria in lymphoma involving FDG-PET and bone marrow biopsies (the Lugano criteria)\\[21\\]\n* Patients with grade 3B follicular lymphoma and transformed indolent lymphoma are included\n* Ages ≥ 18\n* Measurable disease, assessable by radiographic examination with FDG-PET showing involvement\n* Access to archived or fresh\u002Ffrozen tumor biopsies\n* No uncontrolled medical comorbidities\n* Adequate cardiac function (EF \\> or equal to 50%), no unstable angina\n* Adequate renal function (GFR \\> 60)\n* Adequate liver function (liver function tests should be no greater than 2 x upper limit of normal) including normal bilirubin levels, no greater than 2 x upper limit of normal unless patient has a history of Gilbert's disease\n* Adequate marrow reserves as indicated by complete blood count in the judgment of the treating investigator\n\nExclusion Criteria:\n\n* Pregnancy, positive serum HCG within 28 days of enrollment, or breast-feeding\n* Bulky disease greater than 10 cm in any dimension","ALL","18 Years",{"count":75,"type":76},40,"ESTIMATED","INTERVENTIONAL",[79],"PHASE2","The overarching goals of this study are to measure levels of circulating tumor DNA (ctDNA) in patients with early stage diffuse large B cell lymphoma (DLBCL), to assess the change in ctDNA during treatment in order to prospectively identify markers of treatment failure, and to use ctDNA as a future tool for response adapted therapy.",[82],"DLBCL","2026-02-04",{"date":85,"type":86},"2026-02-09","ACTUAL",{"date":88,"type":86},"2019-05-08",{"date":90,"type":76},"2027-06-01",{"name":5,"class":6},1]